Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Price Target at $12.23

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have earned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $12.2308.

CMPX has been the topic of several analyst reports. William Blair started coverage on Compass Therapeutics in a research report on Monday, January 5th. They set an “outperform” rating on the stock. Citizens Jmp initiated coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 price objective on the stock. Cantor Fitzgerald began coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They set an “overweight” rating for the company. D. Boral Capital restated a “buy” rating and set a $30.00 target price on shares of Compass Therapeutics in a research note on Tuesday, January 6th. Finally, Leerink Partners raised shares of Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Vivo Capital LLC raised its stake in Compass Therapeutics by 70.0% during the 2nd quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock valued at $15,713,000 after purchasing an additional 2,487,443 shares during the period. Simplicity Wealth LLC boosted its stake in Compass Therapeutics by 81.8% in the 2nd quarter. Simplicity Wealth LLC now owns 84,636 shares of the company’s stock worth $220,000 after purchasing an additional 38,093 shares during the period. Avanza Fonder AB purchased a new stake in Compass Therapeutics during the 4th quarter valued at approximately $147,000. Caxton Corp grew its holdings in Compass Therapeutics by 23.1% during the 3rd quarter. Caxton Corp now owns 53,503 shares of the company’s stock valued at $187,000 after buying an additional 10,038 shares in the last quarter. Finally, Suvretta Capital Management LLC raised its position in shares of Compass Therapeutics by 97.2% during the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after buying an additional 6,951,666 shares during the last quarter. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Stock Performance

CMPX stock opened at $6.38 on Tuesday. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -14.18 and a beta of 1.45. The business’s 50-day moving average is $5.42 and its two-hundred day moving average is $4.23. Compass Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $6.49.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. Equities analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.